Hannah N. Imlay, MD, MS

Journal Article

1. Brandon H, Truax CM, Zarate ER, Tritle BJ, Imlay (2026). No Increased Risk of Infection Following a Protocol Change to Decrease Duration of Perioperative Antibiotic Prophylaxis in Liver Transplantation. Transplant infectious disease, 28(3), e70192.
2. Kobasuk L, Cisowska T, Howard K, Gabriel C, Wu C, Imlay H, Spivak ES, Nazminia (2026). Clinical outcomes with oral cephalosporins as definitive treatment of Enterobacterales bacteremia from a urinary source based on cefazolin minimum inhibitory concentration. Antimicrobial agents and chemotherapy, 70(4), e0135725.
3. Ciarkowski CE, Howard K, Imlay H, Wu C, Hopkins CL, Vaughn VM, Spivak E (2026). Streamlining antibiotic use in community acquired pneumonia: A quality improvement initiative. Journal of hospital medicine,
4. Payne J, Sutton JD, Blackburn BE, Bansod S, Imlay H, Spivak ES, Pupaibool J, Gililland JM, Certain L (2025). Effect of oral antibiotics after two-stage revision for periprosthetic joint infection on subsequent antibiotic resistance within a national cohort of United States veterans. Journal of bone and joint infection, 10(1), 7-14.
5. Yamauchi J, Raghavan D, Imlay H, Jweehan D, Oygen S, Marineci S, Remport A, Hall IE, Molnar M (2024). Deceased Organ Donor HTLV Screening Practices Postelimination of Universal Screening in the United States. Transplantation direct, 10(10), e1707.
6. Imlay H, Gnann JW Jr, Rooney J, Peddi VR, Wiseman AC, Josephson MA, Kew C, Young JH, Adey DB, Samaniego-Picota M, Whitley RJ, Limaye A (2024). A randomized, placebo-controlled, dose-escalation phase I/II multicenter trial of low-dose cidofovir for BK polyomavirus nephropathy. Transplant infectious disease, e14367.
7. Imlay H, Thorpe A, Vaughn V (2024). When antimicrobial stewardship begins with microbiological test requests: the case of asymptomatic bacteriuria. Current opinion in infectious diseases, 37(6), 565-572.
8. Hosseini-Moghaddam SM, Kothari S, Humar A, Albasata H, Yetmar ZA, Razonable RR, Neofytos D, D'Asaro M, Boggian K, Hirzel C, Khanna N, Manuel O, Mueller NJ, Imlay H, Kabbani D, Tyagi V, Smibert OC, Nasra M, Fontana L, Obeid KM, Apostolopoulou A, Zhang SX, Permpalung N, Alhatimi H, Silverman MS, Guo H, Rogers BA, MacKenzie E, Pisano J, Gioia F, Rapi L, Prasad GVR, Banegas M, Alonso CD, Doss K, Rakita RM, Fishman J (2024). Adjunctive glucocorticoid therapy for Pneumocystis jirovecii pneumonia in solid organ transplant recipients: A multicenter cohort, 2015-2020. American journal of transplantation, 24(4), 653-668.
9. Imlay H, Greenlee SB, Tritle BJ, Fino NF, Spivak E (2024). In-person prospective audit and feedback on an oncology ward: development of an immunocompromised antimicrobial stewardship program. Antimicrobial stewardship & healthcare epidemiology, 4(1), e173.
10. Imlay H, Ciarkowski CE, Bryson-Cahn C, Chan JD, Hartlage WP, Hersh AL, Lynch JB, Martinez-Paz N, Spivak ES, Hardin H, White AT, Wu C, Kassamali Escobar Z, Vaughn V (2024). Validation and generalizability of an asymptomatic bacteriuria metric in critical access hospitals. Infection control and hospital epidemiology, 46(2), 1-6.
11. Ciarkowski CE, Imlay HN, Bryson-Cahn C, Chan JD, Hartlage W, Hersh AL, Lynch JB, Martinez-Paz N, Spivak ES, Hardin H, White AT, Wu C, Vaughn VM, Kassamali Escobar (2024). Antimicrobial stewardship to reduce overtreatment of asymptomatic bacteriuria in critical access hospitals: measuring a quality improvement intervention. Infection control and hospital epidemiology, 46(2), 1-7.
12. Imlay H, Limaye A (2023). Authors' Reply. Transplantation, 107(3), e83.
13. Wychera C, Imlay HN, Duke ER, Faino A, Li-Huang M, Stevens-Ayers T, Davis C, Lange-Sperandio B, Mallhi KK, Hill JA, Boeckh M, Englund JA, Hingorani (2023). BK Viremia and Changes in Estimated Glomerular Filtration Rate in Children and Young Adults after Hematopoietic Cell Transplantation. Transplantation and cellular therapy, 29(3), 187.e1-187.e8.
14. Earl A, Greenlee S, Fong K, Imlay H, Spivak E (2023). Positivity of repeat nasal MRSA PCR screening: a single-center experience. Antimicrobial stewardship & healthcare epidemiology, 3(1), e226.
15. Yamauchi J, Azhar A, Hall IE, Bhalla A, Potluri VS, Tanriover B, Gupta G, Imlay H, Truax C, Balaraman V, Raghavan D, Zimmerman M, Campsen J, Rofaiel G, Baker T, Molnar M (2023). Comparison of Short-Term Outcomes in Kidney Transplant Recipients from SARS-CoV-2-Infected versus Noninfected Deceased Donors. Clinical journal of the American Society of Nephrology, 18(11), 1466-1475.
16. Imlay H, Baum P, Brennan DC, Hanson KE, Hodges MR, Hodowanec AC, Komatsu TE, Ljungman P, Miller V, Natori Y, Nickeleit V, O'Rear J, Pikis A, Randhawa PS, Sawinski D, Singh HK, Westman G, Limaye AP, BK Disease Definitions Working Group of the Transplantation Associated Virus Infection Forum with the Forum for Collaborative Research (2022). Consensus Definitions of BK Polyomavirus Nephropathy in Renal Transplant Recipients for Clinical Trials. Clinical infectious diseases, 75, 1210-1216.
17. Hannah Imlay and Ajit P. Limay (2022). Overview and virology of JC polyomavirus, BK polyomavirus, and other polyomavirus infections. UpToDate Clinical Reference Library,
18. Imlay H, Hodowanec AC, Komatsu TE, O'Rear J, Pikis A, Limaye A (2022). Reply to Author. Clinical infectious diseases, 75, 2047-2048.
19. Imlay H, Wagener MM, Vutien P, Perkins J, Singh N, Limaye A (2022). Increasing Proportion of High-risk Cytomegalovirus Donor-Positive/Recipient-Negative Serostatus in Solid Organ Transplant Recipients. Transplantation,
20. Imlay HN, Kaul DR (2021). Letermovir and Maribavir for the Treatment and Prevention of Cytomegalovirus Infection in Solid Organ and Stem Cell Transplant Recipients. Clin Infect Dis, 73(1), 156-160.
21. Imlay H, Dasgupta S, Boeckh M, Stapleton RD, Rubenfeld GD, Chen Y, Limaye AP (2021). Risk Factors for Cytomegalovirus Reactivation and Association With Outcomes in Critically Ill Adults With Sepsis: A Pooled Analysis of Prospective Studies. J Infect Dis, 223(12), 2108-2112.
22. Fox ER, Shah M, Vinik R, Brown S, Buckel W, Webb B, Zarndt J, Evans M, Mesdaghi P, Imlay HN, Spivak ES (2021). Developing statewide remdesivir use criteria. Am J Health Syst Pharm, 78(8), 732-735.
23. Vutien P, Perkins J, Biggins SW, Reyes J, Imlay H, Limaye AP (2021). Association of Donor and Recipient Cytomegalovirus Serostatus on Graft and Patient Survival in Liver Transplant Recipients. Liver Transpl, 27(9), 1302-1311.
24. Imlay H, Krantz EM, Stohs EJ, Lan KF, Zier J, Kim HN, Rakita RM, Limaye AP, Wald A, Pergam SA, Liu C (2020). Reported ß-Lactam and Other Antibiotic Allergies in Solid Organ and Hematopoietic Cell Transplant Recipients. Clin Infect Dis, 71(7), 1587-1594.
25. Imlay H, Limaye AP (2020). Current Understanding of Cytomegalovirus Reactivation in Critical Illness. J Infect Dis, 221(Suppl 1), S94-S102.
26. Imlay H, Dumitriu Carcoana AO, Fisher CE, Wong B, Rakita RM, Fishbein DP, Limaye AP (2020). Impact of valganciclovir prophylaxis duration on cytomegalovirus disease in high-risk donor seropositive/recipient seronegative heart transplant recipients. Transpl Infect Dis, 22(3), e13255.
27. Imlay H, Xie H, Leisenring WM, Duke ER, Kimball LE, Huang ML, Pergam SA, Hill JA, Jerome KR, Milano F, Nichols WG, Pang PS, Hirsch HH, Limaye AP, Boeckh M (2020). Presentation of BK polyomavirus-associated hemorrhagic cystitis after allogeneic hematopoietic cell transplantation. Blood Adv, 4(4), 617-628.
28. Steinbrink J, Imlay H, Rao K, Riddell J 4th (2019). Identifying causes of persistent HIV viremia in adult patients at an academic medical center. SAGE Open Med, 7, 2050312119851006.
29. Ulrich RJ, Bott J, Imlay H, Lopez K, Cinti S, Rao K (2019). Clostridioides difficile Enteritis in Patients Following Total Colectomy-a Rare but Genuine Clinical Entity. Open Forum Infect Dis, 6(11), ofz409.
30. Imlay H, Whitaker K, Fisher CE, Limaye AP (2018). Clinical characteristics and outcomes of late-onset BK virus nephropathy in kidney and kidney-pancreas transplant recipients. Transpl Infect Dis, 20(4), e12928.
31. Imlay H, Kaul D, Rao K (2016). Risk factors for Clostridium difficile infection in HIV-infected patients. SAGE Open Med, 4, 2050312116684295.

Review

1. Liu C, Rosen EA, Stohs EJ, Imlay H, Nigo M, Gottesdiener LS, So M, Tverdek F, Dadwal S, Gudiol C, Satlin MJ, Seo SK, Trubiano JA, Banerjee R, Hanson KE, Abbo L (2026). Tackling antimicrobial resistance in people who are immunocompromised: leveraging diagnostic and antimicrobial stewardship. The Lancet. Infectious diseases, 26(1), e30-e48.
2. Steinbrink JM, Friedman DZ, Thompson GR, Kauffman CA, Alexander BD, Hanson K, Imlay H, Mycoses Study Group Education & Research Consortium (MSGERC (2026). Fungal diagnostic stewardship in immunocompromised populations: a focus on molds and dimorphic fungi. Clinical microbiology reviews, 39(1), e0024225.
3. Mendoza MA, Imlay (2025). Polyomaviruses After Allogeneic Hematopoietic Stem Cell Transplantation. Viruses, 17(3),
4. Hartlage W, Imlay H, Spivak E (2024). The role of empiric atypical antibiotic coverage in non-severe community-acquired pneumonia. Antimicrobial stewardship & healthcare epidemiology, 4(1), e214.
5. Gorsline CA, Sharma D, Harris CE, Hand J, Imlay H, Stohs EJ, So M, Kumar R (2024). Not Just an Oxymoron: The Utilitarian's Guide to Antimicrobial Stewardship in Transplant Infectious Diseases. Transplant infectious disease, 26(6), e14399.
6. Imlay H, Seibert AM, Hanson K (2023). Pathogen-agnostic immune biomarkers that predict infection after solid organ transplantation. Transplant infectious disease, e14020.
7. Hand J, Imlay (2023). Antimicrobial Stewardship in Immunocompromised Patients: Current State and Future Opportunities. Infectious disease clinics of North America, 37(4), 823-851.
8. Imlay H, Laundy NC, Forrest GN, Slavin M (2022). Shorter antibiotic courses in the immunocompromised: the impossible dream?. Clinical microbiology and infection,
9. Imlay H, Spellberg (2022). Shorter is better: The case for short antibiotic courses for common infections in solid organ transplant recipients. Transplant infectious disease, 24(5), e13896.

Book Chapter

1. Hannah Imlay and Kimberly E. Hanso Infection Surveillance Prior to Transplantation.

Editorial

1. Imlay H, Stohs E (2025). Collateral Damage: Unpacking Antibiotic Risks in Liver Transplantation. Transplant infectious disease, e70044.
2. Imlay H, Hanson K (2023). Updates in Prevention, Diagnosis, and Management of Infections Among Solid Organ Transplant Recipients. Infectious disease clinics of North America, 37(3), xiii-xv.

Letter

1. Imlay H, Dumitriu Carcoana AO, Fisher CE, Wong B, Rakita RM, Fishbein DP, Limaye AP (2021). Examining valganciclovir prophylaxis duration among high-risk donor seropositive/recipient seronegative heart transplant recipients in a larger cohort. [Letter to the editor]. Transpl Infect Dis, 23, e13581.
2. Molnar MZ, Hall IE, Raghavan D, Shihab F, Imlay H, Hanson KE, Gomez CA, Campsen J, Kim R, Baker N, Rofaiel (2021). Kidney transplantation from SARS-CoV-2-positive deceased donor. American journal of transplantation, 22(4), 1280-1282.

Other

1. Heeren JR, Imlay HN, Estes RE, Tinsley NA, Steffey KL, Gray M (2008). Evaluation of foliar-applied insecticides to control pests of alfalfa in Illinois. Section 9, 30-2.

News

• Cómo protegerse durante la temporada respiratoria
• Here's How to Protect Yourself During Respiratory Season
• Common Questions About Influenza